Abstracts Archive - Page 358 of 1683 - ATC Abstracts

2020 American Transplant Congress
Liver Transplantation for Primary Liver Sarcoma in Children-The US Experience from the Scientific Registry for Transplant Recipients (1988-2018)
A. Amin, K. Soltys, S. Ranganathan, G. Bond, A. Khanna, A. Ganoza, Q. Sun, G. Mazariegos, R. Sindhi
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Primary liver sarcomas (PLS) are rare tumors and encompass subtypes with diverse histology and varying outcomes. These subtypes include embryonal sarcoma (ES), rhabdomyosarcoma (RMS),…
2020 American Transplant Congress
Early Recurrence Of Hepatocellular Carcinoma Following Transplantation: Risk Score From A Multi-institutional Study Of > 3000 Patients
P. Tabrizian¹, M. Holzner², V. Agopian³, R. Busuttil³, G. Sapisochin⁴, N. Mehta⁵, F. Yao⁵, J. Roberts⁶, S. Florman¹, M. E. Schwartz¹, T. Ivanics⁷, J. Emond⁸, B. Samstein⁹, R. Brown, MD, MPH⁹, M. Najjar¹⁰, W. Chapman¹¹, M. Doyle¹¹, K. Halazun⁹
¹Transplant, Mount Sinai Medical Center, New York, NY, ²Surgery, Georgetown University Hospital, Washington DC, MD, ³Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Transplant, Univeristy of Toronto, Toronto, ON, Canada, ⁵Transplant, UCSF, San Francisco, CA, ⁶Transplantation, UCSF, San Francisco, CA, ⁷Transplant, University of Toronto, Toronto, ON, Canada, ⁸Transplant, Columbia University Medical Center, New York, NY, ⁹Transplant, Weill Cornell Medical Center, New York, NY, ¹⁰Transplant, Columbia Medical Center, New York, NY, ¹¹Transplant, Washington University School of Medicine, St Louis, MO
*Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC…
2020 American Transplant Congress
The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma
M. L. Goldman¹, K. Zhou², J. L. Dodge¹, F. Yao¹, N. Mehta¹
¹Department of Medicine, UCSF, San Francisco, CA, ²Department of Medicine, USC, Los Angeles, CA
*Purpose: Under current UNOS policy, hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) >1,000 ng/mL are required to show a reduction in AFP to 100 but
2020 American Transplant Congress
Is the Survival Impacted by Multiple Cancer after Liver Transplantation? A Retrospective French National Multicentric Study between 1993-2013
M. Altieri
Chu Caen, Caen, France
*Purpose: Introduction: Despite the great progress made in recent decades, post-liver transplant de novo cancers is one of the leading causes of late complications and…
2020 American Transplant Congress
Bad Actors within Milan Criteria Undergoing OLT- Characterizing Their Pre-Transplant Tumor Behavior and Response to Locoregional Therapy
A. Mathur, E. Baughan, A. Griesemer, M. Najjar, O. Perez, A. Qian, T. Kato, J. Emond
Columbia University, New York, NY
*Purpose: Orthotopic Liver Transplantation (OLT) remains a curative option for hepatocellular carcinoma (HCC). Disparity between the supply and demand for OLT necessitates the transplant of…
2020 American Transplant Congress
Differences in Immunosuppressive Therapy among Liver Retransplantation Recipients in a National Cohort
A. K. Mezochow, P. L. Abt, T. Bittermann
Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: There is no unified consensus as to the preferred immunosuppression (IS) strategy following liver retransplantation (reLT). This study explored: (i) factors associated with induction…
2020 American Transplant Congress
Risk Factors for Hepatic Artery Thrombosis: A Single Center Study with Multiple Surgeons
M. Fitzsimons¹, M. Bindal², J. Buggs³, D. Patino⁴, E. Rogers³, A. Kumar¹, A. Lu³
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁴University of Tampa, Tampa, FL
*Purpose: Hepatic Artery Thrombosis (HAT) is an uncommon complication after liver transplant, but its occurrence can lead to significant and fatal outcomes. Our objective was…
2020 American Transplant Congress
Outcomes of Intra-Operative Steroid Induction in Liver Transplant Recipients
A. Poparad-Stezar, A. Jantz, T. Larson, B. Summers, N. Sulejmani
Henry Ford Hospital, Detroit, MI
*Purpose: Evidence supporting the use of antibody induction (AI) immunosuppression (IS) (antithymocyteglobulin (rATG) and basiliximab (BAS)) for acute rejection (AR) prophylaxis in liver transplant is…
2020 American Transplant Congress
Treatment of De Novo Renal Transplant Recipients with Calcineurin Inhibitor (CNI)-Free, Belatacept+Everolimus-Based Immunosuppression
V. R. Peddi¹, B. Marder², L. Gaite³, J. Oberholzer⁴, R. Goldberg⁵, T. Pearson⁶, H. Yang⁷, L. Allamassey⁸, S. Gao⁸, M. Polinsky⁸, R. N. Formica⁹
¹California Pacific Medical Center, San Francisco, CA, ²Colorado Kidney Care, Denver, CO, ³Hospital Marqués de Valdecilla, Cantabria, Spain, ⁴UVA Health, Charlottesville, VA, ⁵Saint Barnabas Medical Center, Livingston, NJ, ⁶Emory University School of Medicine, Atlanta, GA, ⁷UPMC Pinnacle, Harrisburg, PA, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Yale University School of Medicine, New Haven, CT
*Purpose: Compared with CNI-based immunosuppression, kidney transplant recipients receiving belatacept-based treatment present with a favorable metabolic profile, reduced chronic allograft nephropathy, and improved renal function,…
2020 American Transplant Congress
Comparing Post-Transplant Outcomes in Living and Deceased Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: An Analysis of UNOS Registry
T. Kitajima¹, D. Moonka², S. Yeddula¹, M. Rizzari¹, K. Collins¹, A. Yoshida¹, M. S. Abouljoud¹, S. Nagai¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI
*Purpose: Because of possible short waiting time, living donor liver transplantation (LDLT) for HCC may provide survival benefit compared to deceased donor LT (DDLT). This…